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Objectives: Multiple myeloma (MM) is an incurable B-cell cancer with accumulated clonal abnormal plasma cells in
bone marrow of patients. MCL-1 (myeloid cell leukemia sequence 1) protein is an anti-apoptotic molecule in MM
cells and regulated by pro-inflammatory cytokine IL-6 and downstream signaling molecules STAT3, PI3K and MAPK.
The purpose of this study is to investigate the effect of STAT3, PI3K and MAPK gene silence on MCL-1 expression in
human MM cells and the consequence of cell survival.
Methods: Lentivirus small hairpin RNA (shRNA) interference techniques were utilized to knock down STAT3, PI3K or
MAPK genes. Gene and protein expression was quantified by quantitative real-time PCR and Western Blot. MM cell
apoptosis was examined by annexin-V FITC/propidium iodide staining.
Results: Efficient silence of STAT3, PI3K, MAPK1 or MAPK2 gene robustly abrogated IL-6 enhanced MCL-1 expression
and suppressed MM cell growth. Silencing STAT3 gene inhibited PI3K expression, silencing PI3K markedly abrogated
STAT3 and MAPK production. Inhibition of MAPK2 gene by shMAPK2 suppressed STAT3, PI3K and MAPK1 expression
in the cells. Silencing of STAT3, PI3K and MAPK2 together completely blocked MCL-1 expression in MM cells.
Conclusion: There is a syngeneic effect among the three independent STAT3, PI3K and MAPK2 survival-signaling
pathways related to MCL-1 expression in MM cells. shRNAs silencing of STAT3, PI3K and MAPK2 together could
provide an effective strategy to treat MM.
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Multiple myeloma (MM) is a B-cell blood cancer that char-
acterized with excessive clonal abnormal plasma cells in
the bone marrow [1]. It is the most common hematological
malignancy in USA. As a B-cell lymphoma-2 (BCL-2) fam-
ily member, myeloid cell leukemia-1 (MCL-1) plays critical
roles in promoting the survival of MM cells [2] as well as a
wide range of other cancer cells due to its anti-apoptosis
activities [3]. The mechanism by which Mcl-1 blocks the
progression of apoptosis is through binding and sequester-
ing the pro-apoptotic BH3-only proteins Bim, PUMA,
Noxa, Bak, and Bax [4], preventing pore formation on
mitochondrial membrane of MM cells and the release of
cytochrome c into the cytoplasm. In clinical and preclinical* Correspondence: swallow3956@sina.com; jdeng2@emory.edu
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treat patients with multiple myeloma [5]. Those inhibitors
are small synthetic BH3 mimetic molecules with the potent
capability to bind to anti-apoptotic factors. Monoclonal
antibodies targeting the malfunctioned plasma cells have
been widely used to treat MM patients either alone or
combined with chemotherapy [6].
MCL-1 is a short half-life protein. It is overexpressed in
cancers cells, which contributes to drug resistance to con-
ventional chemotherapy [7,8]. The expression of MCL-1
in MM cells is tightly regulated by survival signaling trig-
gered by cytokines and growth factors in bone marrow
microenvironment [2,9,10]. IL-6 is a key pro-inflammatory
cytokine that activates MCL-1 survival signaling upstream
molecules including signal transducer and activator of
transcription-3 (STAT3), phosphatidylinositol-3 (PI3K),
and Mitogen-activated protein kinase (MAPK) [11]. Those
molecules modulate three independent signaling pathways
that control MCL-1 transcription [2]. Thus, targeting IL-6td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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18S rRNA 5′-cagccacccgagattgagca-3′ 5′-tagtagcgacgggcggtgtg-3′
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therapeutic approach to treat multiple myeloma. In this
study, we investigated the effects of STAT3, PI3K and
MAPK RNA interference on IL-6 induced MCL-1 expres-




Human myeloma cell lines 8226 and U266 were cultured
in RPMI-1640 medium (Hyclone, USA) supplemented
with 10% heat-inactivated fetal bovine serum (FBS)
(Gibco, USA) and penicillin/streptomycin antibiotics at
37°C in a 5% CO2 incubator. 293 T cells were cultured
in DMEM medium with 10% FBS and penicillin/strepto-
mycin. For cell proliferation assay, U266 or 8226 cells
(5,000 cells/well) were cultured in a 96-well plate with
100ul of RPMI-1640 medium for 24 or 48 hours in pres-
ence of IL-6 (5 ng/ml) (R&D, USA).
Gene silencing
STAT3, PI3K and MAPK targeting oligonucleotide se-
quences were chemically synthesized, used for the cloning
of shRNA-encoding sequences, and inserted into a lentiviral
expression vector pGV217 (GeneChem, Shanghai, China).
STAT3: 5′-GGAGCAGCACCTTCAGGATAA-3′, PI3K:
5′-CAAGATAT GCTAACAC TTCAA-3′, MAPK1: 5′-
GACCGGATAACCTTTAAA-3′, MAPK2: 5′-CACCA
CCTGTGATCTCAAGAA-3′, Control RNA: 5′-UUCU
CCGAACGUGUC ACGUTT-3′. The lentiviral vector-
bearing shRNAs were confirmed by DNA sequencing.
Forty-eight hours after co-transfection with pHelper 1.0
and pHelper 2.0 lentiviral packing plasmid (GeneChem)
into 293 T packaging cells using Lipofectamine 2000
(Invitrogen, USA), the lentivirus-containing supernatant
was harvested and used for infection of human U266 and
8226 multiple myeloma cells in presence of 4 μg/mL poly-
brene (Sigma-Aldrich, St. Louis, MO, USA).
Quantitative Real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted from cells as previously de-
scribed [12]. PrimeScript® RT reagent Kit and SYBR®
PremixEx Taq™ II kit were obtained from TAKARA
(Dalian, China) and used for conversion of total RNA
to cDNA and for the detection of mRNA expression.
Each PCR reaction mixture (20 μl) included 10 μl of
SYBR Green Master Mix, 0.4 μl of sense and anti-sense
primers, and 10 ng of cDNA. The PCR reaction mix
was first denatured at 95°C for 10 minutes. PCR was
then run for 40 cycles: denaturation at 95°C for 15 seconds
and annealing at 60°C for 1 minute. The primer sequences
for qRT-PCR were purchased from AuGCT Corporation
as listed in Table 1. According to the manufacturer’s in-
structions, the fold change with 2-ΔΔCt method was usedin qRT-PCR data analysis and β-actin was served as a con-
trol. All reactions were run in triplicate using the IQ-5
Real-Time PCR System (Bio-Rad, USA).
Cell apoptotic assay
U266 or 8266 cells (106 cells/well) were cultured in 12-well
plates in triplicate and transfected with targeted shRNA
against STAT3, PI3K, MAPK1 or MAPK2, or control
shRNAs vectors for 48 h following the manufacturer’s in-
structions. Apoptotic and viable cells fractions were
assessed with annexin-V FITC/propidium iodide staining
(Invitrogen, USA) on a flow cytometer (Becton, USA) fol-
lowing the manufacturer’s instruction. The apoptotic popu-
lations were determined by ModFit software. Alternatively,
The cells were harvested and washed in PBS, followed by
fixation with ice-cold ethanol overnight. The cells were
then washed in PBS and incubated in 1 ml staining solution
(20 ug/ml propidium iodide and 10 U/ml RNaseA) for
30 min at room temperature. The cell cycle distributions
were assayed by fluorescence-activated cell sorting using a
flow cytometer.
MTT assay
Cell growth was assessed with the 3-(4, 5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.
The cells were seeded into wells of a 96-well plate and in-
fected with lentivirus carrying shRNA for 24 and 48 hours
at 37°C. The cells were then treated with MTT solution
(15 μl/well) for 4 hours at 37°C. After gentle removal of cul-
ture supernatant, the cell pellets were dissolved with 200 μl
of Dimethyl sulfoxide (DMSO). Optical density (OD) at
570 nm was read on a FLUOstar OPTIMA machine (BMG
Labtech). Experiments were performed in triplicate.
Western blot
U266 or 8266 cells were harvested 24 or 48 hours after IL-
6 treatment and washed with cold PBS. Total proteins ex-
tracted from the cells using a RIPA cell lysis buffer (Wolsen,
China) were separated on 10% SDS polyacrylamide gels
and electrophoretically transferred to polyvinylidene
difluoride membrane (Millipore, USA). The membranes
were treated with mouse anti-STAT3, rabbit anti-
MCL-1, anti-PI3K or anti-MAPK1/2 antibodies, rabbit
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anti-β-actin antibodies (1:1000 dilution) (Cell Signaling
Technology, USA). The membranes were then reacted
with the HRP-conjugated secondary antibodies before
subjected to enhanced chemiluminescent (ECL) detec-
tion on an ECL machine (Pierce, USA). The blots were
scanned and the band density was measured on the
Quantity One imaging software.
Statistical analysis
All data were presented as mean ± SD (standard devi-
ation). The MCL-1 protein expression levels post IL-6
treatment, cell growth, and percentage of apoptotic cells
in different shRNA silencing were analyzed by One-way
ANOVA. P < 0.05 was considered statistically significant
(*, P < 0.05; **, P < 0.01).
Results
IL-6 stimulation enhanced MCL-1 expression and
myeloma growth
To evaluate the effect of pro-inflammatory cytokine IL-6
on MCL-1 expression and myeloma growth, human
U266 and 8226 multiple myeloma cells were treated with
or without recombinant cytokine IL-6 in vitro. TotalFigure 1 IL-6 enhanced MCL-1 expression and MM cell growth. Huma
IL-6 for 0, 24 or 48 hours. (A) MCL-1 gene expression in the cells was quan
expression was detected by Western blot with anti-MCL-1 specific antibodi
based on β-actin level and in comparison with untreated cells. (D and E) U
MTT assay. Cell growth was presented as OD values. Data represents threeRNA and protein were isolated from the treated cells.
qRT-PCR assay revealed that IL-6 treatment significantly
enhanced MCL-1 gene expression in both U266 and
8226 cells after 48-hour culture compared to the control
without treatment (p < 0.05) (Figure 1A); there was a
slight increase of MCL-1 in the 24-hour treatment of
IL-6, but not significant. Western blot with anti-human
MCL-1 monoclonal antibodies showed that IL-6 treat-
ment (48 hours) significantly enhanced MCL-1 protein
expression levels (Figure 1B), with a 4 fold increase in
U266 cells and a 2.5 fold increase in 8226 cells in compari-
son with no IL-6 treatment control or 24 hours treatment
(p < 0.01) (Figure 1C). While, MCL-1 levels showed no dif-
ference between 24-hour and no IL-6 treatment. Consis-
tently, IL-6 treatment significantly enhanced the growth of
myeloma cells after 48-hour treatment with IL-6 in U266
cell line (Figure 1D) and 8226-cell line, in comparison with
the treatment without IL-6 (p < 0.05) (Figure 1E).
Silencing STAT3, PI3K, MAPK1 or MAPK2 abrogated IL-6
triggered MCL-1 expression in human MM cells
To examine whether silencing MCL-1 upstream signal-
ing modulators STAT3, PI3K and MAPK could abrogate
IL-6 triggered MCL-1 expression in myeloma cells, wen U266 and 8226 MM cells were cultured in RPMI and stimulated with
tified by qRT-PCR. mRNA fold change was presented. (B) MCL-1 protein
es. (C) MCL-1 protein expression in IL-6 treated group was quantified
266 and 8226 MM cell growth after IL-6 treatment was measured by
independent experiments. *, P < 0.05; **, P < 0.01.
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pin RNAs (shRNA) [13] for STAT3 (shSTAT3), PI3K
(shPI3K) and MAPK1/2 (shMAPK1 or shMAPK2), and
transfected the lentiviral vectors into myeloma cells.
Quantification of mRNA levels by qRT-PCR demon-
strated that shSTAT3 and shPI3K markedly reduced
STAT3 and PI3K mRNA expression in U266 myeloma
cells compared to control shRNA treatment (p < 0.01);
shMAPK1 and shMAPK2 significantly reduced MAPK ex-
pression in the cells in comparison with control shRNA
treatment (p < 0.05) (Figure 2A). Western blot confirmed
that silencing mRNA expression markedly reduced STAT3,
PI3K and MAPK protein expression levels in U266 cells
(Figure 2B). The abrogative effects of small hairpin
silencing RNA on targeted STAT3, PI3K and MAPK
gene expressions were also observed in 8226 myeloma cells
in comparison with control shRNA treatment (Figure 2C).
Accordingly, MCL-1 gene expression was significantly
reduced by shSTAT3, shPI3K, shMAPK1 or shMAPK2
(p < 0.05) (Figure 2D).
Interactions among STAT3, PI3K and MAPK signaling on
IL-6 induced MCL-1 gene expression in myeloma cells
To explore the potential interactions among the three sig-
naling molecules on MCL-1 expression in IL-6 treatedFigure 2 Effect of shSTAT3, shPI3K and shMAPK1/2 on MCL-1 gene ex
transfected with lentivirus carrying shSTAT3, PI3K shMAPK1, shMAPK2 or co
STAT3, PI3K and MAPK in U266 cells were quantified by qRT-PCR. The mRN
shRNA treatment group. (B) Protein expression of STAT3, PI3K or MAPK in U
against the protein. (C) mRNA levels of STAT3, PI3K and MAPK in 8226 cells
compared with the shRNA treatment control group. (D) MCL-1 mRNA expr
MCL-1 mRNA in targeted cells was compared with the control shRNA treatmyeloma cells, the protein expressions of STAT3, PI3K,
MAPK and MCL-1 was profiled by Western blot in hu-
man 8226 myeloma cells transfected with shSTAT3-,
shPI3K-, shMAPK1- or shMAPK3-bearing lentivirus. In
comparison with control shRNA, silencing STAT3 protein
expression by shSTAT3 completely blocked PI3K protein
expression and markedly reduced p-ERK1/2, consequently
suppressed the expression of the downstream MCL-1 pro-
tein in the IL-6 treated 8226 cells. However, no inhibitory
effect was observed on total MAPK protein expression
(Figure 3A). We also observed that silencing PI3K with
shPI3K significantly reduced the protein levels of total
STAT3, pSTAT3, total MAPK, the phosphorylation of
MAPK p44, and downstream MCL-1 (Figure 3B). Com-
pared with control shRNA treatment, silencing MAPK1
with shMAPK1 robustly suppressed MCL-1 expression,
but did not affect the protein level of STAT3 and PI3K
(Figure 3C). When silencing MAPK2 expression in 8226
cells, there was a remarkable decrease of STAT3 protein
expression in treated cells in comparison with shRNA
control group (Figure 3D). There was also a slight reduc-
tion of PI3K expression in shMAPK2 treated 8226 cells.
Moreover, silencing STAT3, PI3K and MAPK2 at the same
time completely blocked STAT3, PI3K, MAPK2 expres-
sion, with little MAPK1 expression, leading to the absencepression. Total RNA was isolated from human U266 and 8226 cells
ntrol shRNA in presence of IL-6 (48 hours). (A) mRNA expression of
A levels were presented as fold change in comparison with the control
266 cells was determined by Western blot with specific antibodies
were also quantified by qRT-PCR and presented as fold changes
ession in 8226 cells was quantified by qRT-PCR. The fold change of
ment group. *, P < 0.05; **, P < 0.01.
Figure 3 Interaction among STAT3, PI3K and MAPK. Total protein was isolated from IL-6 treated human 8226 cells transfected with lentivirus
bearing shSTAT3 (A), shPI3K (B), shMAPK1 (C), shMAPK2 (D), or combined shSTAT3 + shPI3K + shMAPK2 (E), and shRNA control. The proteins were
profiled by Western blot with specific antibodies against STAT3, pSTAT3, PI3K, MAPK, pMAPK, MCL-1 or β-actin. Data represented one of two
independent experiments.
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gether, there was an interaction among STAT3, PI3K and
MAPK2 signaling pathways.
STAT3, PI3K and MAPK RNA interference abrogated
myeloma cell growth
To analyze the effect of STAT3, PI3K and MAPK gene
silencing on the apoptosis of targeted myeloma cells, IL-
6 stimulated human U266 or 8226 cells were harvested
48 hours after shRNA-bearing lentivirus treatment. The
cells were stained with annexin-V and propidium iodide.
Flow cytometry analysis showed that silencing STAT3,
PI3K, or MAPK1 or MAPK2 significantly promoted cell
apoptosis in U266 cells as well as in 8226 cells, compared
to control shRNA treatment (p < 0.05) (Figure 4A and 4B).
In U266 cells, targeted shRNA treatment induced an
average of 44-49% cell apoptosis. While control shRNA
group only showed a 33% cell apoptosis. In 8226 cells,
shSTAT3, shPI3K and shMAPK treatments led to a 23-26%
cell apoptosis compared with only a 13% cell apoptosis in
the shRNA control group (p < 0.05). Consequently, targeted
shRNA treatments markedly inhibited the growth of
myeloma cells in both cell lines in comparison with
control shRNA treatments (Figure 4C and D).
Discussion
The findings in this study indicated that RNA silence of
STAT3, PI3K, or MAPK gene using shRNA interference
robustly inhibited MCL-1 expression in IL-6 treated hu-
man MM cells, leading to remarkable myeloma cell
apoptosis. MCL-1 plays critical roles in cancer cell sur-
vival and drug resistance against chemotherapy [8,14,15]
and become a promising therapeutic target for MMtreatment [16]. RNA silencing/interference is a tech-
nique that can specifically and efficiently knocks down
target genes. STAT3, PI3K and MAPK are three key up-
stream signaling molecules that control MCL-1 expres-
sion. It has showed selective targeting MCL-1 or its
upstream modulatory molecules by RNA interference in-
duced cancer cell death [17-20]. Our study extends the
previous studies using shRNA gene interference tech-
nique for targeting oncogenes in MM cells. To our
knowledge, it is the first report showing that efficient
knockdown of PI3K or MAPK gene by shRNA could
sufficiently block MCL-1 expression in MM cells and re-
sulted in consequent cell death, which offers a potential
to utilize shRN/RNA interference as an alternative of
chemotherapy for treat drug-resistant MM treatment.
RNA interference technique has been widely used to in-
vestigate the functional interaction among related genes
by selective silence of one gene. In this study, we also
assessed the mutual effect of shRNA silencing among
STAT3, PI3K and MAPK genes. It was reported that
STAT3 had functional activities in PI3K-driven oncogenic
transformation and there was a crosstalk between STAT3
and PI3K signaling pathways in driving the transformation
of murine glioblastoma [21] and lymphoblastic B-cell
lymphomas [22], and caused drug resistance [23]. Qiang
et al. reported that there is a crosstalk between PI3K and
MAKP pathways in MM cells [24]. Consistent with their
study, we found that silencing MAPK2 but not MAPK1
had marked suppressive effect on PI3K as well as STAT3.
MAPK1/2 signaling network involves many cross-talk
nodes and routes interactive with other cell survival sig-
naling pathways such as PI3K [25], it is not surprising that
silencing MAPK1 and MAPK2 could have distinct effects
Figure 4 Effect of STAT3, PI3K and MAPK gene silencing on MM cell apoptosis and cell growth. Lentirirus-transfected human U266 and 8226
MM cells (bearing shSTAT3, shPI3K, shMAPK or control shRNA) were cultured in RPMI-1640 medium in presence of IL-6 for 48 hours. (A and B) The cells
were harvested and subjected to apoptotic analyses. The percentage of apoptotic cells in U266 or 8226 cells was presented. (C and D) The cell growth
was measured by MTT assay and presented as absorbance values at 570 nm. Data were represented from three independent experiments. *, P < 0.05;
**, P < 0.01.
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our data demonstrated that knockdown one of STAT3,
PI3K and MAPK2 genes likely affected the expression of
the other two genes in human MM cells and support the
evidence that blockade of both PI3K and MAPK pathways
caused a significantly higher percentage of human primary
MM cell death than individual inhibition [26]. These data
suggest that combined targeting IL-6-activated STAT3,
PI3K and MAPK molecules or signaling pathways tend to
provide better clinical treatment for MM patients, consid-
ering the heterogeneous phenotypes of MM and the emer-
ging drug resistance in the course of chemotherapy [27].
In conclusion, we have efficiently delivered lentivirus
shRNA to knock down STAT3, PI3K, MAPK genes and
downstream MCL-1 expression in human MM cells, and
increased cell apoptosis. Selectively silence of MCL-1
upstream signaling molecules STAT3, PI3K and MAPK
by shRNA provides a potent strategy to treat drug-
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